These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 16488554

  • 1. Augmentation of radiation response with the vascular targeting agent ZD6126.
    Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1458-65. PubMed ID: 16488554
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model.
    Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F, Bunn P.
    Mol Cancer Ther; 2004 Aug 01; 3(8):977-83. PubMed ID: 15299080
    [Abstract] [Full Text] [Related]

  • 4. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.
    Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, Dicker AP.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 1):835-42. PubMed ID: 15701874
    [Abstract] [Full Text] [Related]

  • 5. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R.
    Clin Cancer Res; 2006 Jan 15; 12(2):634-42. PubMed ID: 16428510
    [Abstract] [Full Text] [Related]

  • 6. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM, Harari PM.
    Clin Cancer Res; 2000 Jun 15; 6(6):2166-74. PubMed ID: 10873065
    [Abstract] [Full Text] [Related]

  • 7. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Cancer Res; 2002 Jul 01; 62(13):3711-5. PubMed ID: 12097279
    [Abstract] [Full Text] [Related]

  • 8. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ.
    Clin Cancer Res; 2002 Jun 01; 8(6):1974-83. PubMed ID: 12060643
    [Abstract] [Full Text] [Related]

  • 9. ZD6126: a novel small molecule vascular targeting agent.
    Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1497-502. PubMed ID: 12459377
    [Abstract] [Full Text] [Related]

  • 10. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.
    Cancer Res; 2002 Dec 15; 62(24):7247-53. PubMed ID: 12499266
    [Abstract] [Full Text] [Related]

  • 11. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S.
    Clin Cancer Res; 2004 Nov 15; 10(22):7671-6. PubMed ID: 15570000
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 14. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
    Huang SM, Li J, Armstrong EA, Harari PM.
    Cancer Res; 2002 Aug 01; 62(15):4300-6. PubMed ID: 12154033
    [Abstract] [Full Text] [Related]

  • 15. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2002 Dec 01; 54(5):1512-7. PubMed ID: 12459379
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S, Nagasawa H, Uto Y, Hori H, Ohnishi K, Takahashi A, Ohnishi T, Suzuki M, Nagata K, Kinashi Y, Ono K.
    Oncol Rep; 2005 Aug 01; 14(2):393-400. PubMed ID: 16012721
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126.
    Siemann DW, Rojiani AM.
    Int J Radiat Oncol Biol Phys; 2002 May 01; 53(1):164-71. PubMed ID: 12007956
    [Abstract] [Full Text] [Related]

  • 20. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade.
    Li J, Huang S, Armstrong EA, Fowler JF, Harari PM.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1477-85. PubMed ID: 16029810
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.